In recent years, PD-1 and PD-L1 checkpoint inhibitors have been used as therapy for HCC; indeed, immunotherapy is thought to activate T cells and reinvigorate immune surveillance against cancer. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.